Cibus, Inc. (CBUS)

7.10% (1D)

Market Cap	83.16M
Revenue (ttm)	4.75M
Net Income (ttm)	-274.84M
Shares Out	50.10M
EPS (ttm)	-10.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,837,543
Open	1.640
Previous Close	1.550
Day's Range	1.535 - 1.720
52-Week Range	1.400 - 11.750
Beta	1.88
Analysts	Strong Buy
Price Target	22.00 (+1,225.3%)
Earnings Date	May 8, 2025

About CBUS

Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: CBUS
• Website: https://www.cibus.com

Financial Performance

In 2024, Cibus's revenue was $4.26 million, an increase of 134.56% compared to the previous year's $1.82 million. Losses were -$251.39 million, -6.07% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for CBUS stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 1,225.30% from the latest price.

Price Target

$22.0

(1,225.30% upside)

Analyst Consensus: Strong Buy